To study the correlation of peripheral blood F-box and WD repeat domain-containing domain protein7 and myeloid cell leukemia-1 expression levels with the prognosis of Icotinib administration in elderly patients with advanced non-small-cell lung cancer
10.3760/cma.j.issn.0254-9026.2018.08.012
- VernacularTitle:晚期老年非小细胞肺癌患者外周血中泛素连接酶和髓样细胞白血病基因-1的表达与使用埃克替尼预后初探
- Author:
Yi YANG
1
;
Qiaobin GUAN
;
Li GUO
;
Chenyang HAN
Author Information
1. 314001,嘉兴学院附属第二医院药学部
- Keywords:
Carcinoma,non-small-cell lung;
Ubiquitin-protein ligases;
Myeloid cell leukemia-1;
Icotinib
- From:
Chinese Journal of Geriatrics
2018;37(8):888-891
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the correlation of the prognosis of Icotinib administration with the expression levels of F-box and WD repeat domain-containing 7(FBW7) and myeloid cell leukemia-1 (MCL-1) in peripheral blood in elderly patients with advanced non-small-cell lung cancer.Methods A total of 76 patients aged 60 years or over diagnosed with non-small-cell lung cancer(NSCLC) with EGFR-sensitive mutations and under Icotinib treatment were enrolled in this study.FBW7 and MCL-1 mRNA expression levels in peripheral blood were detected by real-time quantitative PCR(RT-QPCR).The correlation of FBW7 and MCL-1 expression levels with clinical and histological parameters,overall survival (OS),and progression-free-survival (PFS) was analyzed.Results The FBW7 expression level and the MCL-1 expression level were negative correlated(r =-0.37,P ＜0.001).High FBW7 expression levels and low MCL-1 expression levels in peripheral blood were associated with improved therapeutic efficacy of Icotinib (P＜0.001) and extended OS and PFS.Cox regression analysis showed that the expression levels of FBW7 and MCL-1 in peripheral blood were independent influencing factors for OS and PFS.Conclusions Patients with high FBW7 expression levels and low MCl-1 expression levels are more likely to benefit from Icotinib treatment.Expression levels for either factor can be used as a predictive indicator for the effectiveness of Icotinib and provide guidance for its clinical use.
